IYRI:BATS- (USD)

ETF | Others |

Last Closing

USD 46.88

Change

-0.85 (-1.78)%

Market Cap

N/A

Volume

0.04M
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-10 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
FBTC Fidelity Wise Origin Bitcoin T..

+0.50 (+0.68%)

USD 16.57B
INDA iShares MSCI India ETF

+1.13 (+2.21%)

USD 8.63B
PAVE Global X U.S. Infrastructure D..

+0.20 (+0.56%)

USD 7.86B
BUFR First Trust Cboe Vest Fund of ..

+0.01 (+0.04%)

USD 6.45B
BOXX Alpha Architect 1-3 Month Box ..

+0.02 (+0.02%)

USD 5.75B
BBUS JPMorgan BetaBuilders U.S. Equ..

+0.12 (+0.13%)

USD 4.20B
ARKB ARK 21Shares Bitcoin ETF

+0.56 (+0.67%)

USD 4.01B
KNG FT Cboe Vest S&P 500® Dividen..

+0.42 (+0.88%)

USD 3.66B
GSUS Goldman Sachs MarketBeta US Eq..

+0.10 (+0.14%)

USD 2.47B
IFRA iShares U.S. Infrastructure ET..

+0.42 (+0.96%)

USD 2.19B

ETFs Containing IYRI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike